Literature DB >> 34468204

Cannabinol and Sleep: Separating Fact from Fiction.

Jamie Corroon1,2.   

Abstract

In recent years, marketers of cannabis (i.e., marijuana) products have claimed that cannabinol (CBN) has unique sleep-promoting effects. Despite a plausible mechanism, it is possible that such claims are merely rooted in cannabis lore. The aim of this narrative review was to answer the question: "Is there sufficient clinical evidence to support claims that CBN has sleep-promoting effects?" A systematic search of PubMed/MEDLINE was performed to evaluate the published evidence. The abstracts of 99 human studies were screened for relevance by the author and reviewed for compliance with the inclusion criteria. The characteristics and principal findings were extracted from eight full-text articles that met inclusion criteria for detailed review. Pre-clinical and clinical research investigating the effects of CBN is dated and limited, with the preponderance of human studies occurring in the 1970-1980s with small sample sizes lacking diversity in sociodemographic characteristics. Studies specifically assessing subjective effects associated with sleep, such as sedation or fatigue, are rare. Most importantly, published clinical trials investigating associations between CBN and validated sleep questionnaires and/or formal polysomnography were not identified in this review. In addition, evidence demonstrating that CBN itself elicits cannabis-like effects in humans is mixed, with the majority of available evidence demonstrating a lack of such an effect. Consequently, there is insufficient published evidence to support sleep-related claims. Randomized controlled trials are needed to substantiate claims made by manufacturers of cannabis products containing CBN. These studies should specifically evaluate its effects on sleep through polysomnography, or at minimum, through validated sleep questionnaires, and use dosages significantly higher than those found in currently available cannabis products marketed for sleep (typically ≤5 mg). Individuals seeking cannabis-derived sleep aids should be skeptical of manufacturers' claims of sleep-promoting effects.

Entities:  

Keywords:  CBN; THC; cannabinoids; cannabis; marijuana; sleep

Mesh:

Substances:

Year:  2021        PMID: 34468204      PMCID: PMC8612407          DOI: 10.1089/can.2021.0006

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  21 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking.

Authors:  E Johansson; A Ohlsson; J E Lindgren; S Agurell; H Gillespie; L E Hollister
Journal:  Biomed Environ Mass Spectrom       Date:  1987-09

3.  A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol.

Authors:  M Perez-Reyes; M C Timmons; K H Davis; E M Wall
Journal:  Experientia       Date:  1973-11-15

4.  Effects of l-delta9- and l-delta8-trans-tetrahydrocannabinol and cannabinol on schedule-controlled behavior of pigeons and rats.

Authors:  J M Frankenheim; D E McMillan; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1971-07       Impact factor: 4.030

5.  Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.

Authors:  M H Rhee; Z Vogel; J Barg; M Bayewitch; R Levy; L Hanus; A Breuer; R Mechoulam
Journal:  J Med Chem       Date:  1997-09-26       Impact factor: 7.446

6.  Intercannabinoid and cannabinoid-ethanol interactions on human performance.

Authors:  K D Bird; T Boleyn; G B Chesher; D M Jackson; G A Starmer; R K Teo
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

7.  Cannabinoid pharmacology: the first 66 years.

Authors:  Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

8.  Acute and subacute bronchial effects of oral cannabinoids.

Authors:  H Gong; D P Tashkin; M S Simmons; B Calvarese; B J Shapiro
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

9.  The weight of nations: an estimation of adult human biomass.

Authors:  Sarah Catherine Walpole; David Prieto-Merino; Phil Edwards; John Cleland; Gretchen Stevens; Ian Roberts
Journal:  BMC Public Health       Date:  2012-06-18       Impact factor: 3.295

10.  Labeling of Cannabidiol Products: A Public Health Perspective.

Authors:  Jamie Corroon; Douglas MacKay; William Dolphin
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-15
View more
  3 in total

Review 1.  Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.

Authors:  Kenneth B Walsh; Amanda E McKinney; Andrea E Holmes
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

Review 2.  Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care.

Authors:  Donald I Abrams
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

Review 3.  Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research.

Authors:  Diego Caprioglio; Hawraz Ibrahim M Amin; Orazio Taglialatela-Scafati; Eduardo Muñoz; Giovanni Appendino
Journal:  Biomolecules       Date:  2022-08-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.